These insights not only elucidate cardiovascular disease mechanisms but also highlight potential GEF‐targeted therapies (e.g., against VAV3, ARHGEF1, TIAM1, or PDZ‐RhoGEF) for hypertension, atherosclerosis, and myocardial regeneration. This evidence concerns the gene ARHGEF1 and cardiovascular disorder.